Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant

Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research